Remdesivir RCT: A randomised clinical trial (RCT) of remdesivir in patients suffering from moderate Covid-19 was published recently. The study found that, patients administered the drug for five days were 65 per cent more likely to achieve better clinical scores compared to those who received the standard care. However, there was no improvement with 10 days of remdesivir. Further, no reduction in hospitalisation, mortality or fall in duration of oxygen requirement was noticed. Besides, the test itself has glaring holes, as the writer of this column points out. He says that the trial showcases the issues with trials such as this one. They usually end with unimpressive and vague results, just like this one did. The fact that it was sponsored by a major pharma player doesn’t add to its credibility, either. Read more
here.